Rigel names Anne-Marie Duliege as Chief Medical Officer

Elliott Grossbard retires but will continue advising on NDA filing for fostamatinib

Rigel Pharmaceuticals, a biotechnology firm focused on the development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology, has appointed Anne-Marie Duliege as Chief Medical Officer.

Duliege replaces Elliott Grossbard, who is retiring from the position after 14 years with the company. Grossbard will remain with the company, advising on the new drug application (NDA) filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura (ITP).

Duliege has extensive experience in the biopharmaceutical industry, including having held leadership positions in clinical research and development at Genentech and Chiron, and most recently serving as Chief of Strategic Development and Head of Immuno-oncology at ChemoCentryx.

From 2004 to 2013, Duliege was a member of the executive team at Affymax. She ultimately held the position of Chief Medical Officer and Head of Research and Clinical Development at this firm.

You may also like

Research & Development

Rigel to concentrate on three of its leading clinical programmes

This will mean cutting its workforce by about 18% or 30 people
Regulatory

Autoimmune diseases – fostamatinib

Spleen tyrosine kinase, or SYK, has potential as a target in various autoimmune conditions, such as rheumatoid arthritis
Research & Development

Drug licensing deals in 2010

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Regulatory

AstraZeneca to pay Rigel up to US$1.25bn in arthritis agreement

AstraZeneca is to make an upfront payment of US$100m to Rigel Pharmaceuticals in an exclusive license agreement to develop fostamatinib disodium (R788), Rigel\'s late-stage investigational product for the treatment of rheumatoid arthritis (RA).
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Subscribe now